JAK Kinase Inhibition Abrogates STAT3 Activation and Head and Neck Squamous Cell Carcinoma Tumor Growth

Neoplasia (United States)

Volumn 17, Issue 3, 2015, Pages 256-264

  Sen, Malabika ^a   Pollock, Netanya I ^a   Black, John ^a   DeGrave, Kara A ^a   Wheeler, Sarah ^a   Freilino, Maria L ^a   Joyce, Sonali ^a   Lui, Vivian W Y ^a   Zeng, Yan ^a   Chiosea, Simion I ^a   Grandis, Jennifer R ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; BETA TUBULIN; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; MESSENGER RNA; STAT3 PROTEIN; STAT5 PROTEIN; TYROSINE; ANTINEOPLASTIC AGENT; JANUS KINASE; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; EC50; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GENE DOSAGE; GENE EXPRESSION; GENETICS; HEAD AND NECK TUMOR; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; GENE DOSAGE; GENE EXPRESSION; HEAD AND NECK NEOPLASMS; HUMANS; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASES; MICE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIMIDINES; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84964693579     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2015.01.003     Document Type: Article

References (36)

1. [1] Shuai, K, Liu, B, Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol 3 (2003), 900–911.
2. [2] Sansone, P, Bromberg, J, Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol 30 (2012), 1005–1014.
3. [3] Kupferman, ME, Jayakumar, A, Zhou, G, Xie, T, Dakak-Yazici, Y, Zhao, M, Ju, J, Mandal, M, Jasser, S, Madden, T, et al. Therapeutic suppression of constitutive and inducible JAK\STAT activation in head and neck squamous cell carcinoma. J Exp Ther Oncol 8 (2009), 117–127.
4. [4] Jatiani, SS, Baker, SJ, Silverman, LR, Reddy, EP, JAK/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies. Genes Cancer 1 (2010), 979–993.
5. [5] Seidel, HM, Lamb, P, Rosen, J, Pharmaceutical intervention in the JAK/STAT signaling pathway. Oncogene 19 (2000), 2645–2656.
6. [6] Rawlings, JS, Rosler, KM, Harrison, DA, The JAK/STAT signaling pathway. J Cell Sci 117 (2004), 1281–1283.
7. [7] Lai, SY, Johnson, FM, Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches. Drug Resist Updat 13 (2010), 67–78.
8. [8] Boudny, V, Kovarik, J, JAK/STAT signaling pathways and cancer. Janus kinases/signal transducers and activators of transcription. Neoplasma 49 (2002), 349–355.
9. [9] Yu, H, Jove, R, The STATs of cancer—new molecular targets come of age. Nat Rev Cancer 4 (2004), 97–105.
10. [10] Lui, VW, Hedberg, ML, Li, H, Vangara, BS, Pendleton, K, Zeng, Y, Lu, Y, Zhang, Q, Du, Y, Gilbert, B, et al. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov 3 (2013), 761–769.
11. V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. Mayo Clin Proc 80 (2005), 947–958.
12. [12] Leeman, RJ, Lui, VW, Grandis, JR, STAT3 as a therapeutic target in head and neck cancer. Expert Opin Biol Ther 6 (2006), 231–241.
13. [13] Sen, M, Grandis, JR, Nucleic acid-based approaches to STAT inhibition. JAKSTAT 1 (2012), 285–291.
14. [14] Sen, M, Thomas, SM, Kim, S, Yeh, JI, Ferris, RL, Johnson, JT, Duvvuri, U, Lee, J, Sahu, N, Joyce, S, et al. First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discov 2 (2012), 694–705.
15. [15] Hedvat, M, Huszar, D, Herrmann, A, Gozgit, JM, Schroeder, A, Sheehy, A, Buettner, R, Proia, D, Kowolik, CM, Xin, H, et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 16 (2009), 487–497.
16. [16] Scuto, A, Krejci, P, Popplewell, L, Wu, J, Wang, Y, Kujawski, M, Kowolik, C, Xin, H, Chen, L, Kretzner, L, et al. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. Leukemia 25 (2011), 538–550.
17. [17] McFarland, BC, Ma, JY, Langford, CP, Gillespie, GY, Yu, H, Zheng, Y, Nozell, SE, Huszar, D, Benveniste, EN, Therapeutic potential of AZD1480 for the treatment of human glioblastoma. Mol Cancer Ther 10 (2011), 2384–2393.
18. [18] Lai, SY, Koppikar, P, Thomas, SM, Childs, EE, Egloff, AM, Seethala, RR, Branstetter, BF, Gooding, WE, Muthukrishnan, A, Mountz, JM, et al. Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms. J Clin Oncol 27 (2009), 1235–1242.
19. [19] Miyaguchi, K, Fukuoka, Y, Mizushima, H, Yasen, M, Nemoto, S, Ishikawa, T, Uetake, H, Tanaka, S, Sugihara, K, Arii, S, et al. Genome-wide integrative analysis revealed a correlation between lengths of copy number segments and corresponding gene expression profile. Bioinformation 7 (2011), 280–284.
20. [20] Koppikar, P, Lui, VW, Man, D, Xi, S, Chai, RL, Nelson, E, Tobey, AB, Grandis, JR, Constitutive activation of signal transducer and activator of transcription 5 contributes to tumor growth, epithelial-mesenchymal transition, and resistance to epidermal growth factor receptor targeting. Clin Cancer Res 14 (2008), 7682–7690.
21. [21] Jeong, EG, Kim, MS, Nam, HK, Min, CK, Lee, S, Chung, YJ, Yoo, NJ, Lee, SH, Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clin Cancer Res 14 (2008), 3716–3721.
22. [22] Xu, C, Liu, Y, Wang, P, Fan, W, Rue, TC, Upton, MP, Houck, JR, Lohavanichbutr, P, Doody, DR, Futran, ND, et al. Integrative analysis of DNA copy number and gene expression in metastatic oral squamous cell carcinoma identifies genes associated with poor survival. Mol Cancer, 9, 2010, 143.
23. [23] Aggarwal, BB, Kunnumakkara, AB, Harikumar, KB, Gupta, SR, Tharakan, ST, Koca, C, Dey, S, Sung, B, Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?. Ann N Y Acad Sci 1171 (2009), 59–76.
24. [24] Johnston, PA, Grandis, JR, STAT3 signaling: anticancer strategies and challenges. Mol Interv 11 (2011), 18–26.
25. [25] Yue, P, Turkson, J, Targeting STAT3 in cancer: how successful are we?. Expert Opin Investig Drugs 18 (2009), 45–56.
26. [26] Sonbol, MB, Firwana, B, Zarzour, A, Morad, M, Rana, V, Tiu, RV, Comprehensive review of JAK inhibitors in myeloproliferative neoplasms. Ther Adv Hematol 4 (2013), 15–35.
27. [27] Nagumo, T, Daisuke, I, Tsukamoto, H, Yasuda, A, Shintani, S, STAT3 as a target of molecular targeting therapy for oral cancer: cell-based screening using inhibitor screening kits. Asian J Oral Maxillofac Surg 23 (2011), 167–171.
28. [28] Lui, VW, Yau, DM, Wong, EY, Ng, YK, Lau, CP, Ho, Y, Chan, JP, Hong, B, Ho, K, Cheung, CS, et al. Cucurbitacin I elicits anoikis sensitization, inhibits cellular invasion and in vivo tumor formation ability of nasopharyngeal carcinoma cells. Carcinogenesis 30 (2009), 2085–2094.
29. [29] Abuzeid, WM, Davis, S, Tang, AL, Saunders, L, Brenner, JC, Lin, J, Fuchs, JR, Light, E, Bradford, CR, Prince, ME, et al. Sensitization of head and neck cancer to cisplatin through the use of a novel curcumin analog. Arch Otolaryngol Head Neck Surg 137 (2011), 499–507.
30. [30] Derenzini, E, Lemoine, M, Buglio, D, Katayama, H, Ji, Y, Davis, RE, Sen, S, Younes, A, The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma. Blood Cancer J, 1, 2011, e46.
31. [31] Gu, L, Liao, Z, Hoang, DT, Dagvadorj, A, Gupta, S, Blackmon, S, Ellsworth, E, Talati, P, Leiby, B, Zinda, M, et al. Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer. Clin Cancer Res 19 (2013), 5658–5674.
32. [32] Lee, JH, Park, KS, Alberobello, AT, Kallakury, B, Weng, MT, Wang, Y, Giaccone, G, The Janus kinases inhibitor AZD1480 attenuates growth of small cell lung cancers in vitro and in vivo. Clin Cancer Res 19 (2013), 6777–6786.
33. [33] Yan, S, Li, Z, Thiele, CJ, Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in neuroblastoma and pediatric sarcomas in vitro and in vivo. Oncotarget 4 (2013), 433–445.
34. [34] Couto, JP, Almeida, A, Daly, L, Sobrinho-Simoes, M, Bromberg, JF, Soares, P, AZD1480 blocks growth and tumorigenesis of RET-activated thyroid cancer cell lines. PLoS One, 7, 2012, e46869.
35. [35] Keysar, SB, Astling, DP, Anderson, RT, Vogler, BW, Bowles, DW, Morton, JJ, Paylor, JJ, Glogowska, MJ, Le, PN, Eagles-Soukup, JR, et al. A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. Mol Oncol 7 (2013), 776–790.
36. [36] Kimple, RJ, Harari, PM, Torres, AD, Yang, RZ, Soriano, BJ, Yu, M, Armstrong, EA, Blitzer, GC, Smith, MA, Lorenz, LD, et al. Development and characterization of HPV-positive and HPV-negative head and neck squamous cell carcinoma tumorgrafts. Clin Cancer Res 19 (2013), 855–864.